<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2604221989
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROPHARM 500MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cipropharm<sup>&reg;</sup></strong> contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. <strong>Cipropharm<sup>&reg;</sup></strong> works by killing bacteria that cause infections. It only works with specific strains of bacteria.</p><p><strong>Adults</strong></p><p><strong>Cipropharm<sup>&reg;</sup></strong> is used in adults to treat the following bacterial infections:</p><p>Respiratory tract infections.</p><p>Long lasting or recurring ear or sinus infections.</p><p>Urinary tract infections.</p><p>Genital tract infections in men and women.</p><p>Gastro-intestinal tract infections and intra-abdominal infections.</p><p>Skin and soft tissue infections.</p><p>Bone and joint infections.</p><p>To prevent infections due to the bacterium <em>Neisseria meningitides.</em></p><p>Anthrax inhalation exposure.</p><p><strong>Cipropharm<sup>&reg;</sup></strong><sup> </sup>may also be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be caused by bacterial infection.</p><p>If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to <strong>Cipropharm<sup>&reg;</sup></strong>.</p><p><strong>Children and adolescents</strong></p><p><strong>Cipropharm<sup>&reg; </sup></strong>is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:</p><p>Lung and bronchial infections in children and adolescents suffering from cystic fibrosis.</p><p>Complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis).</p><p>Anthrax inhalation exposure.</p><p><strong>Cipropharm<sup>&reg; </sup></strong>may also be used to treat other specific severe infections in children and adolescents when your doctor considers this necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cipropharm<sup>&reg;</sup>:</strong></p><p>If you are allergic to the active substance, to other quinolone drugs or to any of the other ingredients of this medicine.</p><p>If you are taking tizanidine.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p><strong>Before taking this medicine: </strong></p><p>You should not take fluoroquinolone/quinolone antibacterial medicines, including <strong>Cipropharm<sup>&reg;</sup></strong>, if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone. In this situation, you should inform your doctor as soon as possible.</p><p><strong>Talk to your doctor before taking Cipropharm<sup>&reg;</sup>:</strong></p><p>If you have ever had kidney problems because your treatment may need to be adjusted.</p><p>If you suffer from epilepsy or other neurological conditions.</p><p>If you have a history of tendon problems during previous treatment with antibiotics such as <strong>Cipropharm<sup>&reg;</sup></strong>.</p><p>If you are diabetic because you may experience a risk of hypoglycaemia with <strong>Cipropharm<sup>&reg;</sup></strong>.</p><p>If you have myasthenia gravis (a type of muscle weakness) because symptoms can be exacerbated.</p><p>If you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</p><p>If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</p><p>If you have been diagnosed with leaking heart valves (heart valve regurgitation).</p><p>If you have a family history of aortic aneurysm or aortic dissection or congenital heart valve disease, or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Sj&ouml;gren&rsquo;s syndrome [an inflammatory autoimmune disease], or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&acute;s disease, high blood pressure, or known atherosclerosis, rheumatoid arthritis [a disease of the joints] or endocarditis [an infection of the heart]).</p><p>If you have heart problems. Caution should be taken when using <strong>Cipropharm<sup>&reg;</sup></strong>, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes.</p><p>If you a member of your family is known to have a deficiency in glucose-6- phosphate dehydrogenase (G6PD), since you may experience a risk of anaemia with ciprofloxacin.</p><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to <strong>Cipropharm<sup>&reg;</sup></strong>. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p><strong>While taking Cipropharm<sup>&reg;</sup></strong></p><p>Tell your doctor immediately, if any of the following occurs while taking <strong>Cipropharm<sup>&reg;</sup></strong>. Your doctor will decide whether treatment with <strong>Cipropharm<sup>&reg; </sup></strong>needs to be stopped.</p><p>Severe, sudden allergic reaction (an anaphylactic reaction/shock, angioedema). Even with the first dose, there is a small chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, sick or faint, or experiencing dizziness when standing up. If this happens, stop taking <strong>Cipropharm<sup>&reg;</sup></strong><sup> </sup>and contact your doctor immediately.</p><p>Prolonged, disabling and potentially irreversible serious side effects. Fluoroquinolone/quinolone antibacterial medicines, including ciprofloxacin, have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. This includes tendon, muscle and joint pain of the upper and lower limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, numbness or burning (paraesthesia), sensory disorders including impairment of vision, taste and smell, and hearing, depression, memory impairment, severe fatigue, and severe sleep disorders.</p><p>If you experience any of these side effects after taking <strong>Cipropharm<sup>&reg;</sup></strong>, contact your doctor immediately prior to continuing treatment. You and your doctor will decide on continuing the treatment considering also an antibiotic from another class.</p><p>Pain and swelling in the joints and inflammation or rupture of tendons may occur rarely. Your risk is increased if you are elderly (above 60 years of age), have received an organ transplant, have kidney problems or if you are being treated with corticosteroids.</p><p>Inflammation and ruptures of tendons may occur within the first 48 hours of treatment and even up to several months after stopping of <strong>Cipropharm<sup>&reg; </sup></strong>therapy. At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking <strong>Cipropharm<sup>&reg;</sup></strong>, contact your doctor and rest the painful area. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture.</p><p>If you feel sudden, severe pain in your abdomen, chest or back, which can be symptoms of aortic aneurysm and dissection, go immediately to an emergency room. Your risk may be increased if you are being treated with systemic corticosteroids.</p><p>If you start experiencing a rapid onset of shortness of breath, especially when you lie down flat in your bed, or you notice swelling of your ankles, feet or abdomen, or a new onset of heart palpitations (sensation of rapid or irregular heartbeat), you should inform a doctor immediately.</p><p>If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If seizure happens, stop taking <strong>Cipropharm<sup>&reg; </sup></strong>and contact your doctor immediately.</p><p>You may rarely experience symptoms of nerve damage (neuropathy) such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. If this happens, stop taking <strong>Cipropharm<sup>&reg; </sup></strong>and inform your doctor immediately in order to prevent the development of potentially irreversible condition.</p><p>You may experience psychiatric reactions even when taking quinolone antibiotics, including <strong>Cipropharm<sup>&reg;</sup></strong>, for the first time. If you suffer from depression or psychosis, your symptoms may become worse under treatment with <strong>Cipropharm<sup>&reg;</sup></strong>. In rare cases, depression or psychosis can progress to suicidal thoughts and self-injurious behaviours such as suicide attempts, or completed suicide. If depression, psychosis, suicide-related thoughts or behaviour occur, contact your doctor immediately.</p><p>Quinolone antibiotics may cause an increase of your blood sugar levels above normal levels (hyperglycaemia), or lowering of your blood sugar levels below normal levels, potentially leading to loss of consciousness (hypoglycaemic coma) in severe cases. This is important for people who have diabetes. If you suffer from diabetes, your blood sugar should be carefully monitored.</p><p>Diarrhea<strong> </strong>may develop while you are taking antibiotics, including <strong>Cipropharm<sup>&reg;</sup></strong>, or even several weeks after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking <strong>Cipropharm<sup>&reg; </sup></strong>and contact your doctor immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements.</p><p>If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately.</p><p>Your skin becomes more sensitive to sunlight or ultraviolet (UV) light<strong> </strong>when taking <strong>Cipropharm<sup>&reg;</sup></strong>. Avoid exposure to strong sunlight, or artificial UV light such as sunbeds.</p><p>Tell the doctor or laboratory staff that you are taking <strong>Cipropharm<sup>&reg; </sup></strong>if you have to provide a blood or urine sample.</p><p>If you suffer from kidney problems, tell the doctor because your dose may need to be adjusted.</p><p><strong>Cipropharm<sup>&reg; </sup></strong>may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, contact your doctor immediately.</p><p><strong>Cipropharm<sup>&reg; </sup></strong>may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is Important to inform your doctor about your medicine.</p><p><strong>Other medicines and Cipropharm<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Do not take<strong> Cipropharm<sup>&reg;</sup> </strong>together with tizanidine because this may cause side effects such as low blood pressure and sleepiness.</p><p>The following medicines are known to interact with <strong>Cipropharm<sup>&reg; </sup></strong>in your body. Taking <strong>Cipropharm<sup>&reg; </sup></strong>together with these medicines can influence the therapeutic effect of those medicines. It can also increase the chance of you getting side effects.</p><p><strong>Tell your doctor if you are taking:</strong></p><p>Vitamin K antagonists (e.g warfarin, acenocoumarol, phenprocoumon, fluindione) or other oral anti-coagulants (to thin the blood).</p><p>Probenecid (for gout).</p><p>Methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis).</p><p>Theophylline (for breathing problems).</p><p>Tizanidine (for muscle spasticity in multiple sclerosis).</p><p>Olanzapine (an antipsychotic).</p><p>Clozapine (an antipsychotic).</p><p>Ropinirole (for Parkinson&rsquo;s disease).</p><p>Phenytoin (for epilepsy).</p><p>Metoclopramide (for nausea and vomiting).</p><p>Ciclosporin (for skin conditions, rheumatoid arthritis and in organ transplantation).</p><p>Other medicines that can alter your heart rhythm: medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.</p><p>Zolpidem (for sleep disorders).</p><p><strong>Cipropharm<sup>&reg; </sup>may increase the levels of the following medicines in your blood:</strong></p><p>Pentoxifylline (for circulatory disorders).</p><p>Caffeine.</p><p>Duloxetine (for depression, diabetic nerve damage or incontinence).</p><p>Lidocaine (for heart conditions or anaesthetic use).</p><p>Sildenafil (e.g for erectile dysfunction).</p><p>Agomelatine (for depression).</p><p><strong>Some medicines reduce the effect of Cipropharm<sup>&reg;</sup>. Tell your doctor if you take or wish to take:</strong></p><p>Antacids.</p><p>Omeprazole.</p><p>Mineral supplements.</p><p>Sucralfate.</p><p>A polymeric phosphate binder (e.g. sevelamer or lanthanum carbonate).</p><p>Medicines or supplements containing calcium, magnesium, aluminium or iron.</p><p>If these preparations are essential, take <strong>Cipropharm<sup>&reg; </sup></strong>about two hours before or no sooner than four hours after them.</p><p><strong>Cipropharm<sup>&reg; </sup>with food and drink</strong></p><p>Unless you take <strong>Cipropharm<sup>&reg; </sup></strong>during meals, do not<strong> </strong>eat or drink any dairy products (such as milk or yoghurt) or drinks with added calcium when you take the tablets, as they may affect the absorption of the active substance.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is preferable to avoid the use of <strong>Cipropharm<sup>&reg; </sup></strong>during pregnancy.</p><p>Do not take <strong>Cipropharm<sup>&reg;</sup></strong> during breast-feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.</p><p><strong>Driving and using machines</strong></p><p><strong>Cipropharm<sup>&reg;</sup></strong> may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to <strong>Cipropharm<sup>&reg;</sup></strong> before driving a vehicle or operating machinery. If in doubt, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will explain to you exactly how much <strong>Cipropharm<sup>&reg; </sup></strong>you will have to take as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p>The treatment usually lasts from 5 to 21 days, but may take longer for severe infections. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure how many tablets to take and how to take <strong>Cipropharm<sup>&reg;</sup></strong>.</p><p>Swallow the tablets with plenty of fluid.</p><p>Do not chew and do not crush the tablets. If you are not able to swallow the tablet, please inform your doctor, so that he could prescribe another formulation more suitable for you.</p><p>Do try to take the tablets at around the same time every day.</p><p>You can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will not seriously affect uptake. However, do not take <strong>Cipropharm<sup>&reg; </sup></strong>tablets with dairy products such as milk or yoghurt or with fortified fruit juices (e.g. calcium-fortified orange juice).</p><p>Remember to drink plenty of fluids while you are taking <strong>Cipropharm<sup>&reg;</sup></strong>.</p><p><strong>If you take more Cipropharm<sup>&reg; </sup>than you should</strong></p><p>If you take more than the prescribed dose, get medical help immediately. If possible, take your tablets or the box with you to show the doctor.</p><p><strong>If you forget to take Cipropharm<sup>&reg;</sup></strong></p><p>If you forget to take <strong>Cipropharm<sup>&reg; </sup></strong>and it is:</p><p>6 hours or more until your next scheduled dose, take your missed dose right away. Then take the next dose at your regular time.</p><p>Less than 6 hours until your next scheduled dose, do not take the missed dose. Take the next dose at your regular time.</p><p>Do not take a double dose to make up for a forgotten dose. Be sure to complete your course of treatment.</p><p><strong>If you stop taking Cipropharm<sup>&reg;</sup></strong></p><p>It is important that you finish the course of treatment even if you begin to feel better after a few days. If you stop taking this medicine too soon, your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.</p><p>If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><u>The following section contains the most serious side effects that you can recognize yourself:</u></strong></p><p><strong>Stop taking Cipropharm<sup>&reg; </sup>and contact you doctor immediately in order to consider another antibiotic treatment if you notice any of the following serious side effects:</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>Seizure.</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>Severe, sudden allergic reaction with symptoms such as: Tightness in the chest, feeling dizzy, sick or faint or experiencing dizziness when standing up (an anaphylactic reaction/shock).</p><p>Muscle weakness, inflammation of the tendons which could lead to rupture of the tendon, particularly affecting the large tendon at the back of the ankle (Achilles tendon).</p><p>A serious life-threatening skin rash, usually in the form of blisters or ulcers in the mouth, throat, nose, eyes and other mucous membranes such as genitals which may progress to widespread blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>Unusual feelings of pain, burning, tingling, numbness or muscle weakness in the extremities (neuropathy).</p><p>A drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS Drug Reaction with Eosinophilia and Systemic Symptoms, AGEP Acute Generalised Exanthematous Pustulosis).</p><p><strong><u>Other side effects which have been observed during treatment with ciprofloxacin are listed below by how likely they are: </u></strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>Nausea, diarrhea.</p><p>Joint pain and joint inflammation in children.</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>Joint pain in adults.</p><p>Fungal superinfections.</p><p>A high concentration of eosinophils, a type of white blood cells.</p><p>Decreased appetite.</p><p>Hyperactivity or agitation.</p><p>Headache, dizziness, sleeping problems, taste disorders.</p><p>Vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), or wind.</p><p>Increased amounts of certain substances in the blood (transaminases and/or bilirubin).</p><p>Rash, itching or hives.</p><p>Poor kidney function.</p><p>Pains in your muscles and bones, feeling unwell (asthenia) or fever.</p><p>Increase in blood alkaline phosphatase (a certain substance in the blood).</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>Muscle pain, inflammation of the joints, increased muscle tone and cramping.</p><p>Inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases).</p><p>Changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or decreased amounts of a blood clotting factor (thrombocytes).</p><p>Allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angio-oedema).</p><p>Increased blood sugar (hyperglycaemia).</p><p>Decreased blood sugar (hypoglycaemia).</p><p>Confusion, disorientation, anxiety reactions, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide) or hallucinations.</p><p>Pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, or giddiness.</p><p>Eyesight problems incl. double vision.</p><p>Tinnitus, loss of hearing, impaired hearing.</p><p>Rapid heartbeat (tachycardia).</p><p>Expansion of blood vessels (vasodilation), low blood pressure, or fainting.</p><p>Shortness of breath, including asthmatic symptoms.</p><p>Liver disorders, jaundice (cholestatic icterus), or hepatitis.</p><p>Sensitivity to light.</p><p>Kidney failure, blood or crystals in the urine, urinary tract inflammation.</p><p>Fluid retention or excessive sweating.</p><p>Increased levels of the enzyme amylase.</p><p><strong>&nbsp;Very rare (may affect up to 1 in 10,000 people):</strong></p><p>A special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal.</p><p>Allergic reaction called serum sickness-like reaction.</p><p>Mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide).</p><p>Migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure and pseudotumor cerebri).</p><p>Visual colour distortions.</p><p>Inflammation of the wall of the blood vessels (vasculitis).</p><p>Pancreatitis.</p><p>Death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure.</p><p>Small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes.</p><p>Worsening of the symptoms of myasthenia gravis.</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>Syndrome associated with impaired water excretion and low levels of sodium (SIADH).</p><p>Feeling highly excited (mania) or feeling great optimism and over activity (hypomania).</p><p>Abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart).</p><p>Influence on blood clotting (in patients treated with Vitamin K antagonists).</p><p>Loss of consciousness due to severe decrease in blood sugar levels (hypoglycaemic coma).</p><p>Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, numbness or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors.</p><p>Cases of an enlargement and weakening of the aortic wall or a tear in the aortic wall (aneurysms and dissections), which may rupture and may be fatal, and of leaking heart valves have been reported in patients receiving fluoroquinolones.</p><p><strong>&nbsp;If any of the side effects get serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Cipropharm<sup>&reg;</sup></strong> tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Cipropharm<sup>&reg;</sup></strong> tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Ciprofloxacin (hydrochloride).</p><p>The other ingredients are Sodium starch glycolate, povidone K30, microcrystalline cellulose, talc, magnesium stearate, Opadry O-YL White (Lactose monohydrate, HPMC/ Hypromellose, Titanium Dioxide, Macrogol/PEG), polyethylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cipropharm® 500 mg Film Coated tablets: White to off white oblong biconvex film coated tablets, engraved with V11on one side and plain on the other side, presented in PVC/PVDC/Alu blisters, intended for oral use.
Pack size: 10 film coated tablets.

To report any side effect (s):
•Saudi Arabia:
The National Pharmacovigilance Center (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
•Other GCC States:
Please contact the relevant competent authority.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Med City Pharma-KSA.</p><p>Tel: 00966920003288</p><p>Fax: 00966126358138</p><p>Mobile: 00966555786968</p><p>P.O .Box: 42512 - Jeddah 21551</p><p>E-mail: MD.admin@Axantia.com</p><p>&nbsp;</p><p><strong>Manufactured by: </strong></p><p>Pharma International Company. Amman &ndash; Jordan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2024     

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>سيبروفارم</strong><strong><sup>&reg; </sup></strong>على المادة الفعالة سيبروفلوكساسين. يعد سيبروفلوكساسين أحد المضادات الحيوية التي تنتمي إلى عائلة فلوروكوينولون. يعمل<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> عن طريق القضاء على البكتيريا التي تسبب الالتهابات. يكون فعال فقط ضد سلالات معينة من البكتيريا.</p><p dir="RTL"><strong>البالغون</strong><br />يستعمل <strong>سيبروفارم</strong><strong><sup>&reg; </sup></strong>للبالغين لعلاج الالتهابات البكتيرية التالية:</p><p dir="RTL">التهابات الجهاز التنفسي.</p><p dir="RTL">التهابات الجيوب الأنفية أو الأذن طويلة الأمد أو المتكررة.</p><p dir="RTL">التهابات الجهاز البولي.</p><p dir="RTL">التهابات الجهاز التناسلي عند الرجال و النساء.</p><p dir="RTL">التهابات الجهاز المعدي المعوي والتهابات داخل البطن.</p><p dir="RTL">التهابات الجلد والأنسجة الرخوة.</p><p dir="RTL">التهابات العظام و المفاصل.</p><p dir="RTL">للوقاية من حدوث الالتهابات الناتجة عن بكتيريا نيسيريا مينينجايتيدز.</p><p dir="RTL">التعرض لاستنشاق الجمرة الخبيثة.</p><p dir="RTL">يمكن استعمال <strong>سيبروفارم</strong><strong><sup>&reg; </sup></strong>أيضا<strong><sup> </sup></strong>لعلاج المرضى الذين يعانون من انخفاض عدد خلايا&nbsp; الدم البيضاء (قلة العدلات) والذين يعانون من حمى يشتبه بأن تكون ناتجة عن التهاب بكتيري.</p><p dir="RTL">إذا كنت تعاني من التهاب حاد أو من التهاب ناتج عن الإصابة&nbsp; بأكثر من نوع واحد من البكتيريا، قد يتم علاجك بمضاد حيوي إضافي بالإضافة لاستعمال<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>.<br /><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">يستعمل <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> للأطفال والمراهقين، تحت إشراف طبي متخصص، لعلاج الالتهابات البكتيرية التالية:</p><p dir="RTL">التهابات الرئة والقصبات الهوائية عند الأطفال والمراهقين الذين يعانون من التليف الكيسي.</p><p dir="RTL">التهابات الجهاز البولي المعقدة، بما في ذلك الالتهابات التي وصلت إلى الكلى (التهاب الكلوة والحويضة).</p><p dir="RTL">التعرض لاستنشاق الجمرة الخبيثة.</p><p dir="RTL">يمكن أيضا استعمال <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><sup> </sup>لعلاج التهابات حادة معينة أخرى عند الأطفال والمراهقين عندما يقرر طبيبك ضرورة ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong> <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> <strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من تحسس للمادة الفعالة، لأي أدوية أخرى تنتمي إلى مجموعة الكوينولون أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">&bull; إذا كنت تتناول تيزانيدين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong><strong>:</strong></p><p dir="RTL"><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong><strong>:</strong></p><p dir="RTL">إذا عانيت من أي آثار جانبية خطيرة عند تناول الكينولون أو الفلوروكينولون سابقا، يجب عدم تناول مضادات الالتهاب كينولون/فلوروكينولون، بما في ذلك <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. في هذه الحاله، يجب التحدث مع طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>: </strong></p><p dir="RTL">إذا عانيت سابقا من مشاكل في الكلى، وذلك لأن علاجك قد يحتاج إلى تعديل.</p><p dir="RTL">إذا كنت تعاني من نوبات الصرع&nbsp; أو أي حالات عصبية أخرى.</p><p dir="RTL">إذا عانيت سابقا من مشاكل في الأوتار خلال فترة العلاج سابقا باستعمال المضادات الحيوية مثل <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت تعاني من داء السكري، وذلك لأنك قد تعاني من انخفاض مستوى السكر في الدم عند تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا كنت تعاني من وهن عضلي وبيل (نوع من ضعف العضلات) وذلك لأن الأعراض قد تتفاقم.</p><p dir="RTL">إذا تم تشخيص إصابتك بتضخم أو &ldquo;انتفاخ&rdquo; الأوعية الدموية الكبيرة (تنفخ الشريان الأورطي أو تنفخ الأوعية الدموية الكبيرة الطرفية).</p><p dir="RTL">إذا عانيت سابقا من نوبات تمزق الشريان الأورطي (تمزق في جدار الشريان الأورطي).</p><p dir="RTL">إذا تم تشخيص إصابتك بتسريب صمامات القلب (ارتجاع صمام القلب).</p><p dir="RTL">إذا كان لديك تاريخ عائلي من تنفخ الشريان الأورطي أو تمزق الشريان الأورطي أو مرض خلقي في صمامات القلب، أو عوامل خطورة أخرى أو ظروف مهيئة لذلك (مثل اضطربات الأنسجة الضامة مثل متلازمة مارفان أو متلازمة إهلرز- دانلوس، متلازمة تيرنر، متلازمة شوغرن [أحد أمراض التهاب المناعة الذاتية]، أو اضطربات الأوعية الدموية مثل التهاب الشريان تاكاياسو (التهاب الأورطي غير المحدد)، التهاب الشريان ذو الخلايا العملاقة، مرض بهجت، ارتفاع ضغط الدم، أو تصلب شرايين المعروف، التهاب المفاصل الروماتزمي [مرض في المفاصل] أو التهاب الطبقة الداخلية للقلب [التهاب القلب]).</p><p dir="RTL">إذا كنت تعاني من مشاكل في القلب. يجب توخي الحذر عند استعمال <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>، إذا كنت تعاني من إطالة فترة QT منذ الولادة أو كان لديك تاريخ عائلي من الإصابة بها (تظهر خلال تخطيط القلب الكهربائي، والتسجيل الكهربائي للقلب)، إذا كنت تعاني من عدم توازن الأملاح في الدم (خاصة انخفاض مستوى البوتاسيوم&nbsp; أو المغنيسيوم في الدم)، إذا كنت تعاني من بطء شديد في نبضات القلب (وتسمى &ldquo;بطء القلب&rdquo;)، إذا كنت تعاني من ضعف عضلة القلب (قصور وظيفة عضلة القلب)، إذا عانيت سابقا من نوبة قلبية (احتشاء عضلة القلب)، إذا كنت أنثى أو من كبار السن أو كنت تتناول أدوية أخرى تسبب تغيرات غير طبيعية في تخطيط القلب الكهربائي.</p><p dir="RTL">إذا كنت تنتمي إلى عائلة معروف بأن لديها تاريخ من نقص إنزيم جلوكوز-6- فوسفات ديهيدروجينيز. حيث قد تعاني من خطر الإصابة بفقر الدم عند تناول سيبروفلوكساسين.</p><p dir="RTL">&nbsp;لعلاج بعض التهابات الجهاز التناسلي، يمكن أن يصف لك طبيبك مضاد حيوي آخر بالإضافة إلى <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. إذا لم تلاحظ أي تحسن في الأعراض بعد 3 أيام من العلاج، الرجاء استشارة طبيبك.</p><p dir="RTL"><strong>خلال</strong><strong> </strong><strong>فترة</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك فورا، إذا عانيت من أي مما يلي أثناء تناولك <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. سيقرر طبيبك إذا كان من الضروري التوقف عن العلاج باستعمال <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><sup>.</sup></p><p dir="RTL">تفاعل تحسسي حاد، و مفاجئ (تفاعل فرط التحسس/ صدمة، وذمة وعائية). حتى إذا عانيت من ذلك من أول جرعة، هناك فرصة صغيرة بأنك قد تعاني من تفاعل تحسسي حاد مع ظهور الأعراض التالية: ضيق في الصدر، الشعور بالدوار، الشعور بالمرض أو الإغماء، أو الشعور بالدوار عند الوقوف. إذا حدث هذا، توقف عن تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> واتصل مع طبيبك فورا.</p><p dir="RTL">آثار جانبية خطيرة طويلة الأمد ومسببة للعجز و من المحتمل أن لا تعود إلى وضعها الطبيعي. ارتبطت الأدوية المضادة للبكتيريا الفلوروكينولون/الكينولون، بما في ذلك سيبروفلوكساسين، بآثار جانبية نادرة جدا ولكنها خطيرة، بعضها طويل الأمد (تستمر لأشهر أو أعوام)، مسببة للعجز و من المحتمل أن لا تعود إلى وضعها الطبيعي. وهذا يتضمن آلام الأوتار، العضلات والمفاصل في الأطراف العلوية والسفلية، صعوبة في المشي، أحاسيس غير الطبيعية مثل الشعور بوخز خفيف، وخز، تنميل، خدر أو حرقة (تشوش الحس)، اضطرابات الحواس بما في ذلك ضعف الرؤية، التذوق والشم، و السمع، اكتئاب، ضعف الذاكرة، الشعور بالتعب الحاد، واضطرابات حادة في النوم.</p><p dir="RTL">إذا عانيت من أي من هذه الآثار الجانبية بعد تناول&nbsp; <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>، اتصل مع طبيبك على الفور قبل الاستمرار في العلاج. ستقرر أنت وطبيبك الاستمرار في العلاج مع الأخذ بعين الاعتبار أيضا استعمال مضاد حيوي من مجموعة أخرى.</p><p dir="RTL">ألم وتورم في المفاصل والتهاب أو تمزق الأوتار قد يحدث نادرا. يزداد خطر الإصابة بذلك إذا كنت من كبار السن (أكبر من 60 عاما)، خضعت لزراعة أعضاء، تعاني من مشاكل في الكلى أو يتم علاجك باستعمال الستيرويدات القشرية.</p><p dir="RTL">قد يحدث التهاب وتمزق في الأوتار خلال أول 48 ساعة من العلاج أو لغاية عدة أشهر بعد التوقف عن العلاج باستعمال<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. عند ظهور أول علامة لأي شعور بالألم أو الالتهاب في الوتر (على سبيل المثال في الكاحل، الرسغ، الكوع، الكتف أو الركبة)، توقف عن تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>، اتصل مع طبيبك و أرح المنطقة المصابة. تجنب القيام بأي تمرين غير ضروري، حيث قد يزيد هذا من خطر تمزق الأوتار.</p><p dir="RTL">إذا شعرت بألم مفاجيء، حاد في البطن، الصدر أو الظهر، الذي يمكن أن يكون من أعراض تنفخ وتمزق الشريان الأورطي، اذهب فورا إلى غرفة الطوارئ. قد يزداد الخطر إذا كان يتم علاجك باستعمال الستيرويدات القشرية الجهازية.</p><p dir="RTL">إذا بدأت تعاني من بداية سريعة في قصر النفس، خصوصا عند الاستلقاء على السرير، أو لاحظت تورم في الكاحلين، القدمين أو البطن، أو بداية الشعور بخفقان القلب على غير المعتاد (الشعور بسرعة أو عدم انتظام نبضات القلب)، يجب إخبار طبيبك فورا.</p><p dir="RTL">إذا كنت تعاني من نوبات الصرع أو حالات عصبية أخرى مثل نقص التروية الدماغية أو السكتة الدماغية، قد تعاني من آثار جانبية تؤثر على الجهاز العصبي المركزي. إذا حدث نوبات الصرع، توقف عن تناول<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> واتصل مع طبيبك فورا.</p><p dir="RTL">قد تعاني نادرا من أعراض تلف الأعصاب (الاعتلال العصبي) مثل ألم، حرقة، وخز، خدر و/أو الشعور بالضعف خصوصا في القدمين والساقين أو اليدين والذراعين. إذا حدث هذا، توقف عن تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> واتصل مع طبيبك على الفور و ذلك للوقاية من احتمالية تطورها إلى حالة غير قابلة للعلاج.</p><p dir="RTL">&nbsp;قد تعاني من تفاعلات نفسية حتى عند تناول المضادات الحيوية كينولون بما في ذلك، <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>، لأول مرة. إذا كنت تعاني من الاكتئاب أو الذهان، قد تسوء الأعراض أثناء العلاج باستعمال <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. في حالات نادرة، يمكن للاكتئاب أو الذهان أن يتطور إلى أفكار انتحارية و سلوك مؤذي للنفس مثل محاولات إنتحار أو الإقدام عليه. إذا حصل اكتئاب، ذهان، أفكار أو سلوكيات مرتبطة بالإنتحار، اتصل مع طبيبك فورا.</p><p dir="RTL">قد تسبب المضادات الحيوية من مجموعة الكوينولون ارتفاع في مستويات السكر في الدم أكثر من المستوى الطبيعي، أو انخفاض مستويات السكر في الدم أقل من المستوى الطبيعي، الذي من المحتمل أن يؤدي إلى فقدان الوعي (غيبوبة انخفاض مستوى السكر) في الحالات الحادة. هذا مهم للأشخاص الذين يعانون من داء السكري. إذا كنت تعاني من داء السكري، يجب مراقبة مستويات السكر في الدم بحذر.</p><p dir="RTL">قد تعاني من الإسهال خلال فترة تناول المضادات الحيوية، بما في ذلك <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>، أو حتى بعد عدة أسابيع من التوقف عن تناولها. إذا ازدادت حدة الاسهال أو استمر طويلا أو لاحظت أن البراز يحتوي على دم أو مخاط، توقف عن تناول<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> و اتصل مع طبيبك فورا، حيث أنه قد يهدد حياتك. لا تتناول الأدوية التي توقف أو تبطئ حركة الأمعاء واتصل مع طبيبك.</p><p dir="RTL">إذا عانيت من ضعف في الرؤية أو إذا كان يبدو أنه قد حدث تأثير على العيون، استشر أخصائي العيون فورا.</p><p dir="RTL">إذا أصبح جلدك أكثر حساسية لأشعة الشمس أو الأشعة فوق البنفسجية عند تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>. تجنب التعرض لأشعة الشمس القوية، أو الأشعة فوق البنفسجية الصناعية مثل الأجهزة التي تستخدم لزيادة اسمرار الجلد.</p><p dir="RTL">أخبر الطبيب أو طاقم المختبر بأنك تتناول<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> إذا كان يجب عليك تزويدهم بعينة دم أو بول.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى، أخبر الطبيب لأن الجرعة قد تحتاج إلى تعديل.</p><p dir="RTL">قد يسبب <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> تلف الكبد. إذا لاحظت أي أعراض مثل فقدان الشهية، اليرقان (اصفرار الجلد)، لون البول داكن، حكة، أو التألم باللمس في منطقة المعدة، اتصل مع طبيبك فورا.</p><p dir="RTL">قد يسبب <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> انخفاض عدد خلايا الدم البيضاء وانخفاض المقاومة للالتهابات. إذا عانيت من التهاب مع ظهور أعراض مثل الحمى وتدهور خطير في الحالة العامة، أو حمى مع ظهور أعراض التهاب موضعي مثل التهاب الحلق/البلعوم/الفم أو مشاكل في المسالك البولية عليك أن تراجع طبيبك فورا. سيتم إجراء فحص للدم للتحقق من احتمالية انخفاض عدد خلايا الدم البيضاء (ندرة المحببات). و من الضروري إخبار طبيبك عن الدواء الذي تتناوله.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL">لا تتناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> بالتزامن مع تيزانيدين لأن ذلك قد يسبب آثاراً جانبية مثل انخفاض ضغط الدم والنعاس.</p><p dir="RTL">تعرف الأدوية التالية بتفاعلها مع <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> داخل جسمك. إن تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> بالتزامن مع هذه الأدوية قد يؤثر على المفعول العلاجي لها. ويمكن أيضا أن يزيد فرصة حدوث الآثار الجانبية.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong>: </strong></p><p dir="RTL">مضادات ڤيتامين ك (مثل وارفارين، أسينوكومارول، فينبروكومون أو فلوينديون) أو أي من مضادات التخثر الأخرى (للوقاية من تجلط الدم).</p><p dir="RTL">بروبنيسيد (لعلاج النقرس).</p><p dir="RTL">ميثوتركسيت (لعلاج أنواع معينة من السرطان، الصدفية، التهاب المفاصل الروماتيزمي).</p><p dir="RTL">ثيوفيلين (لعلاج مشاكل التنفس).</p><p dir="RTL">تيزانيدين (لتشنج العضلات في التصلب المتعدد).</p><p dir="RTL">أولانزابين (أحد مضادات الذهان).</p><p dir="RTL">كلوزابين (أحد مضادات الذهان).</p><p dir="RTL">روبينيرول (لعلاج مرض باركنسون).</p><p dir="RTL">فينيتوين (لعلاج نوبات الصرع).</p><p dir="RTL">ميتوكلوبراميد (لعلاج الغثيان والقيء).</p><p dir="RTL">سيكلوسبورين (لعلاج حالات الجلد، التهاب المفاصل الروماتيزمي وفي حالات زراعة الأعضاء).</p><p dir="RTL">الأدوية الأخرى التي يمكن أن تغير نظمية نبضات القلب: الأدوية التي تنتمي إلى مجموعة مضادات اضطراب نظمية نبضات القلب (مثل كينيدين، هايدروكينيدين، ديسوبيراميد، اميودارون، سوتالول، دوفيتيليد، إبيوتيليد)، مضادات الاكتئاب ثلاثية الحلقات، وبعض مضادات الميكروبات (التي تنتمي إلى مجموعة الماكروليدات)، وبعض مضادات الذهان.</p><p dir="RTL">زولبيديم (لعلاج اضطرابات النوم).</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>يزيد</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>من</strong><strong> </strong><strong>مستويات</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">بنتوكسيفيلين (لعلاج اضطرابات الدورة الدموية).</p><p dir="RTL">كافيين.</p><p dir="RTL">دولوكسيتين (لعلاج الاكتئاب، تلف الأعصاب الناتج عن داء السكري أو سلس البول).</p><p dir="RTL">ليدوكائين (لعلاج حالات أمراض القلب أو يستعمل كمخدر).</p><p dir="RTL">سيلدينافيل (مثلا، لعلاج الضعف الجنسي).</p><p dir="RTL">أجوميلاتين (لعلاج الاكتئاب).</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تقلل</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تأثير</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong>. </strong><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يلي</strong><strong>:</strong></p><p dir="RTL">مضادات الحموضة.</p><p dir="RTL">أوميبرازول.</p><p dir="RTL">المكملات المعدنية.</p><p dir="RTL">سوكرالفيت.</p><p dir="RTL">الأدوية التي تستعمل لربط الفوسفات (مثل: سيڤيليمير أو كربونات اللانثانيوم).</p><p dir="RTL">الأدوية أو المكملات الغذائية المحتوية على الكالسيوم، المغنيسيوم، الألمنيوم أو الحديد.</p><p dir="RTL">إذا كان من الضروري تناول هذه الأدوية، تناول <strong>سيبروفارم</strong><strong><sup>&reg; </sup></strong>قبل ساعتين تقريبا أو بعد تناول هذه الأدوية بما لا يقل عن أربع ساعات.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> <strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong><strong>والشراب</strong></p><p dir="RTL">ما لم تتناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> خلال وجبات الطعام، احرص على عدم أكل أو شرب أي من منتجات الألبان (مثل الحليب أو اللبن) أو المشروبات المضاف إليها الكالسيوم عند تناول الأقراص، حيث قد يؤثر ذلك على امتصاص المادة الفعالة.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنت حامل أو مرضعة، تعتقدين بأنك حاملا أو تخططين للحمل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">يفضل تجنب استعمال <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> خلال فترة الحمل.&nbsp;</p><p dir="RTL">لا تتناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> أثناء الرضاعة الطبيعية لأنه يتم إفراز سيبروفلوكساسين في حليب الثدي ويمكن أن يكون ضاراً لطفلك.<br /><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يجعلك <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> تشعر بأنك في حالة انتباه أقل. يمكن أن تُصاب ببعض الأعراض الجانبية العصبية. ولذلك، تأكد من أنك من استجابتك لتناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> قبل قيادة السيارة أو تشغيل الآلات. إذا كان لديك شك، تحدث مع طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب بشرح طريقة تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> تماما بما في ذلك الجرعة ومدة العلاج. وهذا سوف يعتمد على نوع الالتهاب لديك ودرجة خطورته.</p><p dir="RTL">أخبر الطبيب إذا كنت تعاني من مشاكل في الكلى لأنه قد يكون هناك حاجة لتعديل الجرعة.</p><p dir="RTL">يستمر العلاج عادة من 5 إلى 21 يوم، لكن قد تحتاج لمدة أطول لعلاج الالتهابات الحادة. دائما تناول هذا الدواء تماما كما أخبرك طبيبك. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا من عدد الأقراص التي يجب تناولها و كيفية تناول <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">قم بتناول الأقراص مع كمية وفيرة من السائل.</p><p dir="RTL">لا تقم بمضغ الأقراص أو طحنها. أخبر طبيبك إذا كنت غير قادر على تناول الأقراص، ليتمكن من وصف تركيبة أخرى تناسبك أكثر.</p><p dir="RTL">حاول تناول الأقراص تقريبا في نفس الوقت كل يوم.</p><p dir="RTL">من الممكن تناول الأقراص في وقت الوجبات أو بين الوجبات. إن تناول الكالسيوم كجزء من الوجبة لن يؤثر بشكل خطير على الامتصاص. لكن، لا تتناول أقراص <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong>بشكل متزامن مع منتجات الألبان مثل الحليب أو اللبن أو عصائر الفواكه المدعمة (مثل عصير البرتقال المحتوي على كالسيوم مضاف).</p><p dir="RTL">تذكر بأن تشرب كمية وفيرة من السائل عند تناول هذا الدواء.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> أ<strong>كثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت أكثر مما يجب من الأقراص اطلب المساعدة الطبية فورا، إذا أمكن، قم باصطحاب الأقراص أو العبوة معك ليراها الطبيب.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">إذا نسيت تناول جرعة<strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong> و كان:</p><p dir="RTL">6 ساعات أو أكثر حتى وقت الجرعة التالية، تناول الجرعة التي نسيتها حالا. ثم تناول الجرعة التالية في وقتها المعتاد.</p><p dir="RTL">أقل من 6 ساعات حتى وقت الجرعة التالية، لا تتناول الجرعة التي نسيتها. تناول الجرعة التالية في وقتها المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها. تأكد من إكمال العلاج.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><sup> </sup></p><p dir="RTL">من الضروري إكمال العلاج حتى لو بدأت تشعر بتحسن بعد أيام قليلة. إذا توقفت عن تناول هذا الدواء قبل إنتهاء مدة العلاج، قد يكون الالتهاب لديك لم يتم علاجه بشكل كامل وقد تعود الأعراض بالظهور أو تزداد سوءا. قد يحصل لديك أيضا مقاومة للمضادات الحيوية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استعمال هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong><u>يحتوي</u></strong><strong><u> </u></strong><strong><u>القسم</u></strong><strong><u> </u></strong><strong><u>التالي</u></strong><strong><u> </u></strong><strong><u>على</u></strong><strong><u> </u></strong><strong><u>أخطر</u></strong><strong><u> </u></strong><strong><u>الآثار</u></strong><strong><u> </u></strong><strong><u>الجانبية</u></strong><strong><u> </u></strong><strong><u>التي</u></strong><strong><u> </u></strong><strong><u>يمكنك</u></strong><strong><u> </u></strong><strong><u>التعرف</u></strong><strong><u> </u></strong><strong><u>عليها</u></strong><strong><u> </u></strong><strong><u>بنفسك</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg; </sup></strong><strong>واتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong><strong> </strong><strong>بهدف</strong><strong> </strong><strong>الأخذ</strong><strong> </strong><strong>بعين</strong><strong> </strong><strong>الاعتبار</strong><strong> </strong><strong>العلاج</strong><strong> </strong><strong>باستعمال</strong><strong> </strong><strong>مضاد</strong><strong> </strong><strong>حيوي</strong><strong> </strong><strong>آخر</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">نوبات صرع.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">تفاعل تحسسي مفاجئ، حاد مع ظهور أعراض مثل: ضيق في الصدر، شعور بالدوار،&nbsp; الشعور بالمرض أو الإغماء أو الشعور بالدوار عند الوقوف (تفاعل فرط التحسس/صدمة).</p><p dir="RTL">ضعف في العضلات، التهاب الأوتار الذي قد يؤدي إلى تمزق الأوتار، خصوصا الوتر الكبير في المنطقة الخلفية من الكاحل (الوتر الأخلس).</p><p dir="RTL">طفح جلدي خطير مهدد للحياة، عادة على شكل تنفطات أو تقرحات في الفم، الحلق، الأنف، العيون و الأغشية المخاطية الأخرى مثل الأعضاء التناسلية التي قد تتطور إلى تنفطات و تقشر في الجلد واسع الانتشار (متلازمة ستيڤن- جونسون، تحلل نخري سام في البشرة).</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">شعور غير معتاد بالألم، الحرقة، تنميل، خدر أو ضعف العضلات في الأطراف (اعتلال عصبي).</p><p dir="RTL">تفاعل دوائي الذي يسبب طفح، حمى، التهاب الأعضاء الداخلية، اضطرابات في الدم و أمراض جهازية (تفاعل ناتج عن تناول الأدوية ويرافقه كثرة الحمضات وأعراض جهازية، طفح دوائي بثري).</p><p dir="RTL"><strong><u>الآثار</u></strong><strong><u> </u></strong><strong><u>الجانبية</u></strong><strong><u> </u></strong><strong><u>الأخرى</u></strong><strong><u> </u></strong><strong><u>التي</u></strong><strong><u> </u></strong><strong><u>لوحظت</u></strong><strong><u> </u></strong><strong><u>أثناء</u></strong><strong><u> </u></strong><strong><u>العلاج</u></strong><strong><u> </u></strong><strong><u>باستعمال</u></strong><strong><u> </u></strong><strong><u>سيبروفلوكساسين</u></strong><strong><u> </u></strong><strong><u>مذكورة</u></strong><strong><u> </u></strong><strong><u>أدناه</u></strong><strong><u> </u></strong><strong><u>حسب</u></strong><strong><u> </u></strong><strong><u>احتمالية</u></strong><strong><u> </u></strong><strong><u>حدوثها</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">الشعور بالغثيان، إسهال.</p><p dir="RTL">ألم في المفاصل و التهاب في المفاصل عند الأطفال.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">ألم في المفاصل عند البالغين.</p><p dir="RTL">الإصابة بالتهاب فطري إضافي.</p><p dir="RTL">زيادة الحمضات، نوع من خلايا الدم البيضاء.</p><p dir="RTL">قلة الشهية.</p><p dir="RTL">زيادة النشاط أو الهياج.</p><p dir="RTL">صداع، الشعور بالدوار، مشاكل النوم، أو اضطرابات حاسة التذوق.</p><p dir="RTL">قيء، ألم في البطن، مشاكل في الهضم مثل اضطرابات المعدة (عسر الهضم/حرقة)، أو غازات.</p><p dir="RTL">زيادة كمية مواد معينة في الدم (ترانزأمينز و/أو بيليروبين).</p><p dir="RTL">طفح، حكة، أو شرى.</p><p dir="RTL">ضعف وظائف الكلى.</p><p dir="RTL">ألم في العضلات و العظام، الشعور بالضعف على غير المعتاد (وهن)، أو حمى.</p><p dir="RTL">زيادة ألكالاين فوسفاتيز في الدم (مادة معينة في الدم).</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">ألم في العضلات، التهاب المفاصل، زيادة توتر العضلات و تشنجات.</p><p dir="RTL">التهاب الأمعاء (التهاب القولون) المرتبط باستعمال المضادات الحيوية (يمكن أن يسبب الوفاة في حالات نادرة جدًا).</p><p dir="RTL">تغيرات في عدد خلايا الدم (قلة كريات الدم البيضاء، زيادة عدد كريات الدم البيضاء، قلة العدلات، فقر الدم)، زيادة أو نقصان في كميات عامل تخثر الدم (الصفيحات الدموية).</p><p dir="RTL">تفاعلات تحسسية، تورم (وذمة)، تورم سريع في الجلد و الأغشية المخاطية (وذمة وعائية).</p><p dir="RTL">ارتفاع مستوى السكر في الدم.</p><p dir="RTL">انخفاض مستوى السكر في الدم.</p><p dir="RTL">ارتباك، الشعور بالتوهان، تفاعلات القلق، أحلام غريبة، اكتئاب (من المحتمل أن يؤدي إلى أفكار انتحارية، محاولات انتحار، أو الإقدام عليه) أو هلوسات.</p><p dir="RTL">الإحساس بوخز خفيف، حساسية غير معتادة لمنبهات الحواس، ضعف حاسة اللمس، رعاش، أو الشعور بالدوار.</p><p dir="RTL">مشاكل في الرؤية بما في ذلك ازدواجية الرؤية.</p><p dir="RTL">طنين، فقدان السمع، ضعف السمع.</p><p dir="RTL">نبضات قلب سريعة (خفقان).</p><p dir="RTL">توسع الأوعية الدموية، انخفاض ضغط الدم، أو إغماء.</p><p dir="RTL">قصر النفس، بما في ذلك أعراض الربو.</p><p dir="RTL">اضطرابات في الكبد، يرقان، أو التهاب الكبد.</p><p dir="RTL">التحسس للضوء.</p><p dir="RTL">قصور وظيفة الكلى، ظهور دم أو بلورات في البول، التهاب في الجهاز البولي.</p><p dir="RTL">احتباس السوائل أو فرط التعرق.</p><p dir="RTL">ارتفاع مستويات إنزيم أميليز.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">نوع خاص من انخفاض عدد خلايا الدم (فقر الدم الانحلالي)؛ انخفاض خطير في نوع من خلايا الدم البيضاء (ندرة المحببات)، انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية (قلة الكريات الشاملة)، والتي قد تكون قاتل؛ و تثبيط نخاع العظام؛ والتي قد تكون قاتلة.</p><p dir="RTL">تفاعلات تحسسية تعرف بتفاعلات داء المصل.</p><p dir="RTL">الاضطرابات العقلية (التفاعلات الذهانية التي من المحتمل أن تؤدي إلى الأفكار الانتحارية، ومحاولات الانتحار أوالأقدام على&nbsp; الانتحار).</p><p dir="RTL">صداع نصفي، تغيرات في التنسيق، عدم ثبات المشية (اضطراب المشي)، اضطراب في حاسة الشم (اضطرابات شمية)، زيادة الضغط على الدماغ (ارتفاع الضغط داخل الجمجمة أو ورم كاذب داخل الدماغ).</p><p dir="RTL">تشوهات الألوان البصرية.</p><p dir="RTL">التهاب في جدار الأوعية الدموية (الأوعية الدموية).</p><p dir="RTL">التهاب البنكرياس.</p><p dir="RTL">موت خلايا الكبد (نخر كبدي) الذي يؤدي نادرا إلى قصور وظيفة الكبد المهدد للحياة.</p><p dir="RTL">نقط نزيف صغيرة، بحجم أثر الدبوس تحت الجلد (الحبرة)، أنواع مختلفة من هيجان الجلد أو الطفح.</p><p dir="RTL">ازدياد أعراض الوهن العضلي الوبيل سوءا.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">المتلازمة المرتبطة بضعف إخراج الماء و انخفاض مستوى الصوديوم في الدم (متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول).</p><p dir="RTL">الشعور بارتفاع المزاج (هوس) أو التفاؤل بشكل كبير و زيادة النشاط (هوس خفيف).</p><p dir="RTL">سرعة غير طبيعية في نظمية&nbsp; نبضات القلب، عدم انتظام في نظمية نبضات القلب المهددة للحياة، تغيير في نظمية نبضات القلب (تسمى &lsquo;إطالة فترة QT ، تظهر في تخطيط القلب، والنشاط الكهربائي للقلب).</p><p dir="RTL">التأثير على تجلط الدم (في المرضى الذين تم علاجهم بمضادات فيتامين ك).</p><p dir="RTL">فقدان الوعي نتيجة الانخفاض الحاد في مستويات السكر في الدم (غيبوبة انخفاض مستوى السكر).</p><p dir="RTL">في حالات نادرة جدا من التفاعلات الدوائية طويلة الأمد (تصل إلى أشهر أو أعوام) أو المستمرة، مثل التهاب الأوتار، تمزق الأوتار، ألم المفاصل، ألم في الأطراف، صعوبة في المشي، شعور غير طبيعي مثل الشعور بوخز خفيف، وخز، تنميل، الشعور بالحرقة، خدر أو ألم (اعتلال في الأعصاب)، اكتئاب، الشعور بالتعب، اضطرابات في النوم، ضعف الذاكرة، كذلك ضعف السمع، الرؤية، التذوق و الشم مرتبطة بتناول المضادات الحيوية الكوينولون و الفلوروكوينولون، في بعض الحالات بغض النظر عن عوامل الخطر الموجودة سابقا.</p><p dir="RTL">تم تسجيل حالات تضخم وضعف في جدار الأبهر أو تمزق في جدار الأبهر (تنفخ الأوعية الدموية و تمزق) ، التي قد تتمزق وقد تسبب الوفاة، كما تم تسجيل حالات تسريب في صمامات القلب عند المرضى الذين يتناولون الفلوروكوينولون.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>ازدادت</strong><strong> </strong><strong>خطورة</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>حدوث</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة،</strong><strong> </strong><strong>يرجى</strong><strong> </strong><strong>إخبار</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل أقراص <strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong>بعد تاريخ انتهاء الصلاحية (EXP) المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>يحتوي</strong><strong> </strong><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أقراص</strong><strong>:</strong></p><p dir="RTL">المادة الفعالة سيبروفلوكساسين (هيدروكلوريد).</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right">المكونات الأخرى هي جلايكوليت نشا الصوديوم، بوڤيدون ك 03، ميكروكريستالين سيليلوز، تلك، ستيرات المغنيسيوم، أوبادري II أبيض (لاكتوز مونوهيدرات، هيدروكسي بروبيل ميثيل سيليلوز/هيبروميلوز، ثاني أكسيد التيتانيوم، ماكروجول/ بولي إيثيلين جلايكول)، بولي إيثيلين جلايكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سيبروفارم</strong><strong><sup>&reg;</sup></strong><strong> 500 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>مغلفة</strong><strong>: </strong>هي أقراص بيضاء اللون مائلة إلى الصفرة، بيضاوية الشكل، محدبة الوجهين، محفور V11 على أحد الأوجه،<strong> </strong>معبأة في أشرطة بي ڤي سي/بي ڤي دي سي/ ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 10 قرص مغلف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني:&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; </strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p dir="RTL">بريد الكتروني: info@medcitypharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه النشرة لا تحتوي على جميع المعلومات عن المستحضر. إذا كان لديك أية أسئلة أو لم تكن متأكدا من أي شيء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2024              
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cipropharm® 500 mg film-coated tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cipropharm® 500 mg film-coated tablets: Each film-coated tablet contains 500 mg Ciprofloxacin (hydrochloride).

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets. 

Cipropharm® 500 mg Film Coated tablets: White to off white oblong biconvex film coated tablets, engraved with V11 on one side and plain on the other side, presented in PVC/PVDC/Alu blisters, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Cipropharm<sup>&reg; </sup></strong>mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong>Adults </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower respiratory tract infections due to Gram-negative bacteria:</p><p>- Exacerbation of chronic obstructive pulmonary disease. In exacerbation of chronic obstructive pulmonary disease <strong>Cipropharm<sup>&reg; </sup></strong>should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.</p><p>- Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis.</p><p>- Pneumonia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic suppurative otitis media.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infections.</p><p>- Uncomplicated acute cystitis. In uncomplicated acute cystitis <strong>Cipropharm<sup>&reg; </sup></strong>should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.</p><p>- Acute pyelonephritis.</p><p>- Complicated urinary tract infections.</p><p>- Bacterial prostatitis.</p><p>&bull; Genital tract infections:</p><p>- Gonococcal uretritis and cervicitis due to susceptible Neisseria gonorrhoeae.</p><p>- Epididymo-orchitis including cases due to susceptible Neisseria gonorrhoeae.</p><p>- Pelvic inflammatory disease including cases due to susceptible Neisseria gonorrhoeae.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the gastro-intestinal tract (e.g. travellers&rsquo; diarrhoea).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra-abdominal infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the skin and soft tissue caused by Gram-negative bacteria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignant external otitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the bones and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prophylaxis of invasive infections due to Neisseria meningitides.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhalation anthrax (post-exposure prophylaxis and curative treatment).</p><p>Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p><strong>Children and adolescents </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Broncho-pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections and acute pyelonephritis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhalation anthrax (post-exposure prophylaxis and curative treatment).</p><p>Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0"><tbody><tr><td style="width:2.0%">&nbsp;</td><td><p><strong>Posology </strong></p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>Treatment of infections due to certain bacteria (e.g. Pseudomonas aeruginosa, Acinetobacter or Staphylococci) may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><strong><u>Adults</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with Ciprofloxacin)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top"><p>Acute exacerbation of chronic sinusitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Malignant external otitis</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td><td style="vertical-align:top"><p>28 days up to 3 months</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Urinary tract infections</p><p>(see section 4.4)</p></td><td rowspan="2" style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily to 500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>In pre-menopausal women, 500 mg single dose may be used</p></td></tr><tr><td style="vertical-align:top"><p>Complicated cystitis, Acute pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial prostatitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks (acute) to 4 to 6 weeks (chronic)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Genital tract infections</p></td><td style="vertical-align:top"><p>Gonococcal uretritis and cervicitis</p><p>due to susceptible Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td style="vertical-align:top"><p>Epididymo-orchitis and pelvic inflammatory diseases</p><p>including cases due to susceptible Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 14 days</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections of the gastro-intestinal tract and intra-abdominal infections</p></td><td style="vertical-align:top"><p>Diarrhoea caused by bacterial pathogens including <em>Shigella </em>spp. other than <em>Shigella dysenteriae</em> type 1 and empirical treatment of severe travellers&#39; diarrhoea</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1 day</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by <em>Shigella dysenteriae</em> type 1</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by <em>Vibrio cholerae</em></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Typhoid fever</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>5 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the skin and soft tissue</p><p>by Gram-negative bacteria &nbsp;</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>max. of 3 months</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neutropenic patients with fever that is suspected to be due to a bacterial infection</p><p><strong>Cipropharm<sup>&reg;</sup></strong> should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>Therapy should be continued over the entire period of neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prophylaxis of invasive infections due to <em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>60 days from the confirmation of <em>Bacillus anthracis</em> exposure</p></td></tr></tbody></table><p><strong><u>Paediatric population</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with Ciprofloxacin)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cystic fibrosis</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections and pyelonephritis</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose.</p></td><td style="vertical-align:top"><p>60 days from the confirmation of <em>Bacillus anthracis</em> exposure</p></td></tr><tr><td style="vertical-align:top"><p>Other severe infections</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>According to the type of infections</p></td></tr></tbody></table><p><strong><u>Elderly patients </u></strong></p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient&rsquo;s creatinine clearance.</p><p><strong><u>Patients with renal and hepatic impairment </u></strong></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance</strong></p><p><strong>[mL/min/1.73 m&sup2;]</strong></p></td><td style="vertical-align:top"><p><strong>Serum Creatinine</strong></p><p><strong>[&micro;mol/L]</strong></p></td><td style="vertical-align:top"><p><strong>Oral Dose</strong></p><p><strong>[mg]</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>&lt; 124</p></td><td style="vertical-align:top"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>124 to 168</p></td><td style="vertical-align:top"><p>250-500 mg every 12 h</p></td></tr><tr><td style="vertical-align:top"><p><u>&lt;</u>30</p></td><td style="vertical-align:top"><p>&gt;169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>&gt;169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p><p>(after dialysis)</p></td></tr><tr><td style="vertical-align:top"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top"><p>&gt;169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function, no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><strong><u>Method of administration</u></strong></p><p>Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit -juice (e.g. calcium-fortified orange juice) (see section 4.5).</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p><p>Ciprofloxacin tablets should not be crushed and therefore are not suitable for the treatment of adult and pediatric patients who cannot swallow tablets. In those patients another formulation (oral suspension) can be used.</p><p>If a dose is missed, it should be taken anytime but not later than 6 hours prior to the next scheduled dose. If less than 6 hours remain before the next dose, the missed dose should not be taken and treatment should be continued as prescribed with the next scheduled dose. Double doses should not be taken to compensate for a missed dose.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1. 
•	Concomitant administration of ciprofloxacin and tizanidine (see section 4.5). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Ciprofloxacin<strong><sup> </sup></strong>should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with <strong>Cipropharm<sup>&reg; </sup></strong>should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).</p><p><strong>Severe infections and mixed infections with Gram-positive and anaerobic pathogens </strong></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.</p><p><strong>Streptococcal Infections (including Streptococcus pneumoniae) </strong></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.</p><p><strong>Genital tract infections </strong></p><p>Gonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae isolates.</p><p>Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitis only if ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded.</p><p>For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><strong>Urinary tract infections </strong></p><p>Resistance to fluoroquinolones of Escherichia coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in Escherichia coli to fluoroquinolones.</p><p>The single dose of ciprofloxacin, that may be used in uncomplicated cystitis in pre-menopausal women, is expected to be associated with lower efficacy than the longer treatment duration. This is all the more to be taken into account as regards the increasing resistance level of Escherichia coli to quinolones.</p><p><strong>Intra-abdominal infections </strong></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.</p><p><strong>Travellers&rsquo; diarrhoea </strong></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><strong>Infections of the bones and joints </strong></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><strong>Inhalational anthrax </strong></p><p>Use in humans is based on in-vitro susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><strong>Paediatric population </strong></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue (see section 4.8).</p><p><strong>Broncho-pulmonary infections in cystic fibrosis </strong></p><p>Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><strong>Complicated urinary tract infections and pyelonephritis </strong></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1-17 years.</p><p><strong>Other specific severe infections </strong></p><p>Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><strong>Hypersensitivity </strong></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p><strong>Prolonged, disabling and potentially irreversible serious adverse drug reactions </strong></p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. <strong>Cipropharm<sup>&reg; </sup></strong>should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p><strong>Tendinitis and tendon rupture </strong></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment (see section 4.8). The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.</p><p>At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with <strong>Cipropharm<sup>&reg; </sup></strong>should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur.</p><p><strong>Patients with myasthenia gravis</strong></p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p><strong>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence </strong></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet&acute;s disease, hypertension, rheumatoid arthritis) or additionally.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&rsquo;s syndrome) or additionally</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p><p><strong>Vision disorders </strong></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><strong>Photosensitivity </strong></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><strong>Seizures </strong></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8).</p><p><strong>Peripheral neuropathy </strong></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with Ciprofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8).</p><p><strong>Psychiatric reactions </strong></p><p>Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. If depression, psychotic reactions, suicide-related thoughts, or behaviour occur, ciprofloxacin should be discontinued.</p><p><strong>Cardiac disorders </strong></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital long QT syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia).</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p><strong>Dysglycaemia </strong></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported (see section 4.8), usually in elderly diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.</p><p><strong>Gastrointestinal System </strong></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p><strong>Renal and urinary system </strong></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><strong>Impaired renal function </strong></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><strong>Hepatobiliary system </strong></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><strong>Glucose-6-phosphate dehydrogenase deficiency </strong></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.</p><p><strong>Resistance </strong></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by Staphylococcus and Pseudomonas species.</p><p><strong>Cytochrome P450 </strong></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine). Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co-administration of ciprofloxacin and tizanidine is contra-indicated.</p><p><strong>Methotrexate </strong></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><strong>Interaction with tests </strong></p><p>The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drugs known to prolong QT interval </strong></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p><strong>Chelation Complex Formation </strong></p><p>The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p><strong>Food and Dairy Products </strong></p><p>Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.</p><p><strong>Probenecid </strong></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><strong>Metoclopramide </strong></p><p>Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.</p><p>Omeprazole</p><p>Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of Cmax and AUC of ciprofloxacin.</p><p><strong><u>Effects of ciprofloxacin on other medicinal products: </u></strong></p><p><strong>Tizanidine </strong></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><strong>Methotrexate </strong></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><strong>Theophylline </strong></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p><strong>Other xanthine derivatives </strong></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><strong>Phenytoin </strong></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><strong>Cyclosporin </strong></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><strong>Vitamin K antagonists </strong></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).</p><p><strong>Duloxetine </strong></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and Cmax of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><strong>Ropinirole </strong></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of Cmax and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p><strong>Lidocaine </strong></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><strong>Clozapine </strong></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><strong>Sildenafil </strong></p><p>Cmax and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><strong>Agomelatine </strong></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see &lsquo;Cytochrome P450&rsquo; in section 4.4).</p><p><strong>Zolpidem </strong></p><p>Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><strong>Breast-feeding </strong></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100.0%"><tbody><tr><td style="width:.38%">&nbsp;</td><td><p style="text-align:left">The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.</p><p style="text-align:left">ADRs derived from clinical studies and post-marketing surveillance with ciprofloxacin (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left"><strong>Common</strong></p><p style="text-align:left">&ge;1/100 to &lt; 1/10</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left"><strong>Uncommon</strong></p><p style="text-align:left">&ge;1/1 000 to &lt; 1/100</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left"><strong>Rare</strong></p><p style="text-align:left">&ge;1/10 000 to &lt; 1/1 000</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left"><strong>Very Rare</strong></p><p style="text-align:left">&lt; 1/10 000</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left"><strong>Frequency not known</strong></p><p style="text-align:left">(cannot be estimated from available data)</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Mycotic superinfections</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Eosinophilia</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Leukopenia</p><p style="text-align:left">Anaemia</p><p style="text-align:left">Neutropenia</p><p style="text-align:left">Leukocytosis</p><p style="text-align:left">Thrombocytopenia</p><p style="text-align:left">Thrombocytaemia</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Haemolytic anaemia</p><p style="text-align:left">Agranulocytosis</p><p style="text-align:left">Pancytopenia (life-threatening)</p><p style="text-align:left">Bone marrow depression (life-threatening)</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Allergic reaction</p><p style="text-align:left">Allergic oedema / angiooedema</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Anaphylactic reaction</p><p style="text-align:left">Anaphylactic shock (life-threatening) (see section 4.4)</p><p style="text-align:left">Serum sickness-like reaction</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Decreased appetite, Anorexia</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Hyperglycaemia</p><p style="text-align:left">Hypoglycaemia (see section 4.4)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Psychomotor hyperactivity / agitation</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Confusion and disorientation</p><p style="text-align:left">Anxiety reaction</p><p style="text-align:left">Abnormal dreams</p><p style="text-align:left">Depression (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p style="text-align:left">Hallucinations</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide)</p><p style="text-align:left">(see section 4.4)</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Headache</p><p style="text-align:left">Dizziness</p><p style="text-align:left">Sleep disorders</p><p style="text-align:left">Taste disorders</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Par- and Dysaesthesia</p><p style="text-align:left">Hypoaesthesia</p><p style="text-align:left">Tremor</p><p style="text-align:left">Seizures (including status epilepticus see section 4.4)</p><p style="text-align:left">Vertigo</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Migraine</p><p style="text-align:left">Disturbed coordination</p><p style="text-align:left">Gait disturbance Olfactory nerve disorders</p><p style="text-align:left">Intracranial hypertension</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">Peripheral neuropathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Eye Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Visual disturbances (e.g. diplopia)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Visual colour distortions</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Ear and Labyrinth Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Tinnitus</p><p style="text-align:left">Hearing loss / Hearing impaired</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Tachycardia</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">Ventricular arrhythmiaand torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see section 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Vasodilatation</p><p style="text-align:left">Hypotension</p><p style="text-align:left">Syncope</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Vasculitis</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">Nausea</p><p style="text-align:left">Diarrhoea</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Vomiting</p><p style="text-align:left">Gastro-intestinal and abdominal pains</p><p style="text-align:left">Dyspepsia</p><p style="text-align:left">Flatulence</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">&nbsp;Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Pancreatitis</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Increase in transaminases</p><p style="text-align:left">Increased bilirubin</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Hepatic impairment</p><p style="text-align:left">Cholestatic icterus</p><p style="text-align:left">Hepatitis</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Rash</p><p style="text-align:left">Pruritus</p><p style="text-align:left">Urticaria</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Petechiae</p><p style="text-align:left">Erythema multiforme</p><p style="text-align:left">Erythema nodosum</p><p style="text-align:left">Stevens-Johnson syndrome (potentially life-threatening)</p><p style="text-align:left">Toxic epidermal necrolysis (potentially life-threatening)</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">Acute generalised exanthematous pustulosis (AGEP)</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Musculo-skeletal, Connective Tissue and Bone Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Musculo-skeletal pain (e.g. extremity pain, back pain, chest pain)</p><p style="text-align:left">Arthralgia</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Myalgia</p><p style="text-align:left">Arthritis</p><p style="text-align:left">Increased muscle tone and cramping</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">Muscular weakness</p><p style="text-align:left">Tendinitis</p><p style="text-align:left">Tendon rupture (predominantly Achilles tendon) (see section 4.4)</p><p style="text-align:left">Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Renal impairment</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Renal failure</p><p style="text-align:left">Haematuria</p><p style="text-align:left">Crystalluria (see section 4.4)</p><p style="text-align:left">Tubulointerstitial nephritis</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Asthenia</p><p style="text-align:left">Fever</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Oedema</p><p style="text-align:left">Sweating (hyperhidrosis)</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:18.4%"><p style="text-align:left"><strong>Investigations</strong></p></td><td style="vertical-align:top; width:11.36%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.46%"><p style="text-align:left">Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top; width:19.86%"><p style="text-align:left">Increased amylase</p></td><td style="vertical-align:top; width:17.2%"><p style="text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:16.72%"><p style="text-align:left">International normalised ratio increased (in patients treated with Vitamin K antagonists)</p></td></tr></tbody></table><p>* Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p><strong><u>Paediatric population </u></strong></p><p>The incidence of arthropathy (arthralgia, arthritis), mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p>&nbsp;</p><p><strong>To report any side effect (s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses.</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0"><tbody><tr><td style="width:2.0%">&nbsp;</td><td><p><strong>Pharmacotherapeutic group:</strong> Fluoroquinolones, <strong>ATC code:</strong> J01MA02.</p><p><strong>Mechanism of action </strong></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><strong>Pharmacokinetic/pharmacodynamic relationship </strong></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><strong>Mechanism of resistance </strong></p><p>In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in-vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.</p><p>Plasmid-mediated resistance encoded by qnr-genes has been reported.</p><p><strong>Spectrum of antibacterial activity </strong></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p>EUCAST Recommendations</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae</p></td><td style="vertical-align:top"><p>S &le;0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Salmonella spp.</p></td></tr></tbody></table><p>&nbsp;</p></td><td style="vertical-align:top"><p>S &le;0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Pseudomonas spp</p></td><td style="vertical-align:top"><p>S &le;0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Acinetobacter spp</p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Haemophilus influenzae</p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.6 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Moraxella catarrhalis</p></td><td style="vertical-align:top"><p>S &le; 0.125 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Neisseria gonorrhoeae</p></td><td style="vertical-align:top"><p>S &le;0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Neisseria meningitidis</p></td><td style="vertical-align:top"><p>S &le;0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.03 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related breakpoints*</p></td><td style="vertical-align:top"><p>S &le;0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr></tbody></table><p>1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-positive micro-organisms</u></strong></p><p>Bacillus anthracis (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-negative micro-organisms</u></strong></p><p>Aeromonas spp.</p><p>Brucella spp.</p><p>Citrobacter koseri</p><p>Francisella tularensis</p><p>Haemophilus ducreyi</p><p>Haemophilus influenzae*</p><p>Legionella spp.</p><p>Moraxella catarrhalis*</p><p>Neisseria meningitidis</p><p>Pasteurella spp.</p><p>Salmonella spp.*</p><p>Shigella spp.*</p><p>Vibrio spp.</p><p>Yersinia pestis</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Anaerobic micro-organisms</u></strong></p><p>Mobiluncus</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Other micro-organisms</u></strong></p><p>Chlamydia trachomatis ($)</p><p>Chlamydia pneumoniae ($)</p><p>Mycoplasma hominis ($)</p><p>Mycoplasma pneumoniae ($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-positive micro-organisms</u></strong></p><p>Enterococcus faecalis ($)</p><p>Staphylococcus spp. *(2)</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-negative micro-organisms</u></strong></p><p>Acinetobacter baumannii+</p><p>Burkholderia cepacia+ *</p><p>Campylobacter spp.+ *</p><p>Citrobacter freundii*</p><p>Enterobacter aerogenes</p><p>Enterobacter cloacae*</p><p>Escherichia coli*</p><p>Klebsiella oxytoca</p><p>Klebsiella pneumoniae*</p><p>Morganella morganii*</p><p>Neisseria gonorrhoeae*</p><p>Proteus mirabilis*</p><p>Proteus vulgaris*</p><p>Providencia spp.</p><p>Pseudomonas aeruginosa*</p><p>Pseudomonas fluorescens</p><p>Serratia marcescens*</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Anaerobic micro-organisms</u></strong></p><p>Peptostreptococcus spp.</p><p>Propionibacterium acnes</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>INHERENTLY RESISTANT ORGANISMS</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-positive micro-organisms</u></strong></p><p>Actinomyces</p><p>Enteroccus faecium</p><p>Listeria monocytogenes</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram-negative micro-organisms</u></strong></p><p>Stenotrophomonas maltophilia</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Anaerobic micro-organisms</u></strong></p><p>Excepted as listed above</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Other micro-organisms</u></strong></p><p>Mycoplasma genitalium</p><p>Ureaplasma urealitycum</p></td></tr></tbody></table><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p>+ Resistance rate &ge; 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on in-vitro susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.</p><p>(2): Methicillin-resistant S. aureus very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption </strong></p><p>Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.</p><p>Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.</p><p>The absolute bioavailability is approximately 70-80%.</p><p>A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.</p><p><strong>Distribution </strong></p><p>Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><strong>Biotransformation </strong></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display in-vitro antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><strong>Elimination </strong></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Excretion of ciprofloxacin (% of dose)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral administration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urine</p></td><td style="vertical-align:top"><p>Faeces</p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>44.7</p></td><td style="vertical-align:top"><p>25.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolites (M1- M4)</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>7.5</p></td></tr></tbody></table><p>Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><strong>Paediatric patients </strong></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children Cmax and AUC were not age-dependent (above one year of age). No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p style="text-align:justify">Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin <em>in-vitro</em> and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p style="text-align:justify"><strong><em><u>Articular tolerability: </u></em></strong></p><p style="text-align:justify">As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are are Sodium starch glycolate, povidone K30, microcrystalline cellulose, talc, magnesium stearate, Opadry O-YL White (Lactose monohydrate, HPMC/ Hypromellose, Titanium Dioxide, Macrogol/PEG), polyethylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Cipropharm<sup>&reg;</sup> 500 mg Film Coated tablets: </strong>White to off white oblong biconvex film coated tablets, engraved with V11 on one side and plain on the other side, presented in PVC/PVDC/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 10 film coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 00966920003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail: info@medcitypharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>